PARP inhibitors in prostate cancer: Choices of tests and how to test?

ASCO 2020: Breast cancer roundup

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML

COVID-19: Optimising supportive care during active cancer treatment

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

ASCO 2020: Updates in renal cancer

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer

Highlights from ASCO 2020

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway